Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Alkem Laboratories Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended September 30, 2016
Alkem Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here
Alkem Laboratories gets US FDA observations on Daman plant
Alkem Laboratories says it will prepare a detailed response with corrective and preventive measures to address the US FDA observations Update on US FDA Inspection at Alkems Daman Facility
Alkem Laboratories Ltd has informed BSE that US FDA had conducted an inspection at the Companys manufacturing facility located at Daman, India from September 20 to September 29, 2016.In this regard, the Company has received the inspection report which contains thirteen 483 observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA Observations and the same is proposed... Closure of Trading Window
Alkem Laboratories Ltd has informed BSE that, in terms of Companys Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from September 29, 2016 until, the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and half year ended September 30, 2016 are communicated to the Stock Exchanges. Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Alkem Laboratories Ltd has informed BSE regarding the details of Voting results at the 42nd Annual General Meeting (AGM) of the Company held on September 02, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizer's Report and Proceedings of the Meeting in this regard. Outcome of Board Meeting
Alkem Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 12, 2016 approved further investment upto Rs. 250 Million, in Equity shares of Cachet Pharmaceuticals Private Limited, subsidiary of the Company.
Alkem Laboratories Q1 profit rises 17.12% to Rs238.79 crore
Net sales of Alkem Laboratories stood at `1,439.36 crore in the June quarter as against `1,196.03 crore in the year-ago period Opening of Trading Window
Alkem Laboratories Ltd has informed BSE regarding "Intimation of Opening of Trading Window". Press Release and Analyst presentation on Q1FY17 Results
Alkem Laboratories Ltd has informed BSE about Press Release and Analyst presentation on Q1FY17 Results.